Skip to main navigation Skip to search Skip to main content

Pathophysiology of lymphedema—Is there a chance for medication treatment?

  • Geoffrey E. Hespe
  • , Gabriela Garcia Nores
  • , Jung Ju Huang*
  • , Babak J. Mehrara
  • *Corresponding author for this work
  • Memorial Sloan-Kettering Cancer Center

Research output: Contribution to journalReview articlepeer-review

36 Scopus citations

Abstract

Lymphedema is a common morbid after cancer treatment. The disease characterizes with progressive inflammatory process that result in irreversible fibrosis. Its chronology and progressive disease character often impacts the quality of life of cancer survivors. The pathophysiology of lymphedema remains unclear and the disease remains non-curable. In this article, we reviewed available studies of lymphedema and concluded possible treatment strategies for lymphedema. J. Surg. Oncol. 2017;115:96–98.

Original languageEnglish
Pages (from-to)96-98
Number of pages3
JournalJournal of Surgical Oncology
Volume115
Issue number1
DOIs
StatePublished - 01 01 2017

Bibliographical note

Publisher Copyright:
© 2016 Wiley Periodicals, Inc.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • T-cell
  • inflammation
  • lymphedema

Fingerprint

Dive into the research topics of 'Pathophysiology of lymphedema—Is there a chance for medication treatment?'. Together they form a unique fingerprint.

Cite this